Congress expands federal funding for addiction and mental illness treatment
H.R. 4030 — Treatment Continuity Act of 2025 · Filed by Neal Dunn (R-FL) · 3 cosponsors · Introduced Jun 17, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal law to expand a Health and Human Services grant program (Section 509 of the Public Health Service Act) to prioritize funding for long-acting injectable medications, lab testing, and clinical training to treat substance use disorders and serious mental illness. The bill requires HHS to report annually to Congress on treatment outcomes and applies to all new grants made after enactment.
Why we flagged it
The bill's operative mechanism is straightforward: it amends an existing HHS grant program to broaden eligible treatment modalities for substance use disorder and serious mental illness, with mandatory congressional reporting. This is a direct expansion of public health authority and funding scope.
What the text implies
- The bill does not appropriate new funds—it redirects existing Section 509 grant authority toward long-acting injectables and related services. Actual funding expansion depends on congressional appropriations decisions.
- Annual reporting requirement creates accountability mechanism but does not specify metrics, benchmarks, or consequences for underperformance, leaving implementation discretion to HHS.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers of long-acting injectable medications (buprenorphine, naltrexone, antip; healthcare providers and clinics receiving Section 509 grants; clinical training and workforce development organizations